---
schema_version: "secwatch.filing_event.v1"
accession: "0001193125-25-139959"
form_type: "8-K"
ticker: "VRCA"
cik: "0001660334"
company_name: "Verrica Pharmaceuticals Inc."
filed_at: "2025-06-12T23:59:59+00:00"
generated_at: "2026-05-19T10:46:34.820287+00:00"
event_type: "debt"
sentiment: "negative"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Verrica amends credit agreement, waives going concern covenant through Dec 2025

## Summary
- Sixth amendment waives Section 7.1(b) and 7.1(c) going concern qualifications for Q2'25, Q3'25, and FY2025 financial statements.
- Company paid amendment fee of $110,465.12 to lenders (OrbiMed Royalty & Credit Opportunities IV, LP).
- Original credit agreement dated July 26, 2023; all other terms unchanged.
- Waiver addresses potential default risk from going concern audit language in upcoming filings.

## SEC filing metadata
- accession: 0001193125-25-139959
- form_type: 8-K
- ticker: VRCA
- cik: 0001660334
- company_name: Verrica Pharmaceuticals Inc.
- filed_at: 2025-06-12T23:59:59+00:00
- event_type: debt
- sentiment: negative
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 1.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1660334/000119312525139959/0001193125-25-139959-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1660334/000119312525139959/d949783d8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001193125-25-139959
- JSON: https://secwatch.observer/filing/0001193125-25-139959.json
- Plain text: https://secwatch.observer/filing/0001193125-25-139959.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.